Xiu-Hua Wan

Prof. Dr. Xiu-Hua Wan

Beijing Tongren Hospital, Capital Medical university, Beijing, China.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
MYMao Ying-Yan
Mao Ying-Yan
LMLi Meng
Li Meng
WJWang Jin-Da
Wang Jin-Da
WKWang Kai-Jie
Wang Kai-Jie
ZJZhang Jing-Shang
Zhang Jing-Shang
XWXiu-Hua Wan
Xiu-Hua Wan

27 December 2021 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
KCKai Cao
Kai Cao
JZJingshang Zhang
Jingshang Zhang
JWJinda Wang
Jinda Wang
MYMayinuer Yusufu
Mayinuer Yusufu
SJShanshan Jin
Shanshan Jin
XWXiu-Hua Wan
Xiu-Hua Wan
Purpose: To compare the efficacy, safety, predictability and visual quality between implantable collamer lens (ICL) implantation and small incision lenticule extraction (SMILE) for high myopia correction in adults. Methods: A systematic review and meta-analysis was conducted. A comprehensive literature search was done based on databases including PubMed, Science Direct, Embase, and the Cochrane Central Register of Controlled Trials. The efficacy index, safety index, changes in Snellen lines of corrected distance visual acuity (CDVA), predictability (difference between post-operative and attempted spherical equivalent error, SER), incidence of halos, and change in higher-order aberrations (HOAs) were compared. Mean difference (MD) and 95% confidence interval (CI) was used to estimate continuous outcomes, risk ratio (RR) and 95%CI was used to estimate categorical outcomes. Results: Five observational studies involving 555 eyes were included in this review. Studies’ sample sizes (eyes) ranged from 76 to 197. Subjects’ refraction ranged from -6 diopter (D) to -12D. Study duration of most researches were 6 months or 12 months. Compared to SMILE, ICL implantation showed better efficacy index (MD=0.09, 95%CI:0.01 to 0.16) and better safety index (MD=0.08, 95%CI: 0.00 to 0.16). Compared with SMILE, more ICL-treated eyes gained one or more Snellen lines of CDVA (RR=1.54, 95%CI:1.28 to 1.86), more gained two or more lines (RR=2.09, 95%CI:1.40 to 3.13), less lost one or more lines (RR=0.17, 95%CI:0.05 to 0.63). There was no difference in predictability between two treatments, RRs of predictability of within ±0.5D and ±1D were 1.13 (95%CI: 0.94 to 1.36) and 1.00 (95%CI: 0.98 to 1.02). Compared with SMILE, ICL implantation came with a higher risk of halos [RR=1.79, 95%CI: 1.48 to 2.16] and less increase in total HOAs (MD=-0.23, 95%CI: -0.42 to -0.03). Conclusion: Compared with SMILE, ICL implantation showed a higher risk of halos, but equal performance on SER control, and better performance on efficacy index, safety index, CDVA improvement and HOAs control. Overall, ICL implantation might be a better choice for high myopia correction in adults.

6 August 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
JZJing-Shang Zhang
Jing-Shang Zhang
JLJing Li
Jing Li
JWJin-Da Wang
Jin-Da Wang
YXYing Xiong
Ying Xiong
KCKai Cao
Kai Cao
XWXiu-Hua Wan
Xiu-Hua Wan

11 January 2023 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MLMeng Li
Meng Li
JWJin-Da Wang
Jin-Da Wang
JZJing-Shang Zhang
Jing-Shang Zhang
YMYing-Yan Mao
Ying-Yan Mao
KCKai Cao
Kai Cao
XWXiu-Hua Wan
Xiu-Hua Wan
Purpose: To compare the accuracy of three intraocular lens (IOL) formulas in Chinese cataract patients with prior radial keratotomy (RK). Methods: Medical records of cataract patients with prior RK at Beijing Tongren Hospital were retrospectively analysed. The absolute error (AE) was calculated as the absolute difference between the actual postoperative spherical equivalent and the predicted spherical equivalent. The AE and percentages of eyes with AE within 0.5D, 1.0D, and 2.0D for three formulas [Barrett True-K, Holladay 1 (D–K), Haigis] were calculated and compared. Results: Forty-seven eyes of 28 cataract patients were included. The Median AE (MedAE) was significantly different among the three formulas (P < 0.001). The MedAE was lowest for the Barrett True-K formula (0.62), followed by the Haigis (0.76), and Holladay 1 (D–K) (1.16). The percentages of eyes with AE within 0.5D, and 1.0D were significantly different among the 3 formulas (P = 0.009, and P < 0.001). The Barrett True-K formula achieved the highest percentages (46.8%) of eyes with AE within 0.5D. Haigis achieved the highest percentages (70.21%) of eyes with AE within 1.0 D. Conclusions: Barrett True-K is the most accurate IOL power calculation formula among the 3 formulas and Haigis is an alternative choice. Considering the relatively lower accuracy of IOL formulas in cataract patients with prior RK, newer and more accurate IOL formulas are desirable.

25 July 2022 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
FZFeng Zhang
Feng Zhang
WBWei Bian
Wei Bian
YCYanyun Chen
Yanyun Chen
JLJianying Liu
Jianying Liu
XWXiu-Hua Wan
Xiu-Hua Wan
Background: The degeneration of retinal pigmented epithelium (RPE) cells results in severe diseases, such as age-related macular degeneration (AMD) that causes blindness in millions of individuals. Results: We report that targeting GMP-AMP (cGAMP) synthase (cGAS) alleviates Alu RNA-induced immune responses and cytotoxicity in RPE. We find that the deletion of cGAS in RPE inhibits the Alu RNA-stimulated interferon production. cGAS deficiency also protects RPE from cell death triggered by Alu RNA. Importantly, two natural chemicals, epigallocatechin gallate (EGCG) and resveratrol (RSVL), are effective in suppressing the immunogenic and cytotoxic effect of Alu RNA in RPE. Conclusions: Our findings further demonstrate the crucial role of cGAS in the Alu RNA-induced RPE damage and present EGCG and RSVL as potential therapies for AMD and other RPE degeneration-related conditions.

1 October 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
YJYu-Feng Jian
Yu-Feng Jian
JZJing-Shang Zhang
Jing-Shang Zhang
XWXiu-Hua Wan
Xiu-Hua Wan
Glucocorticoids (GCs) remain a cornerstone therapy for noninfectious uveitis and autoimmune disorders; however, chronic administration is strongly associated with sight-threatening complications, particularly glucocorticoid-induced cataracts (GIC). This comprehensive review synthesizes current evidence on the molecular pathogenesis, epidemiological patterns, and clinical management of GIC. Epidemiological analyses indicate that over 50% of patients receiving systemic corticosteroids for > 60 days develop ocular complications, with cataract formation (36%) and glaucoma (16%) representing the predominant sequelae. Histopathologically, GIC manifests as posterior subcapsular opacities, mechanistically linked to oxidative stress, epithelial-mesenchymal transition (EMT), vimentin dysregulation, Na+/K+-ATPase inhibition, apoptosis, and endoplasmic reticulum (ER) stress. Risk stratification models identify cumulative GC dose (> 20,000 mg/m² prednisolone equivalents), treatment duration (> 6 months), and administration route (oral > topical > intravitreal) as critical determinants of cataractogenesis. Although early-stage GIC is clinically silent, progressive opacification leads to debilitating visual acuity loss, photophobia, and impaired quality of life. Current interventions encompass antioxidants, molecular targeting strategies, advanced drug delivery systems, and glucocorticoid-sparing agents. Through systematic integration of epidemiology, pathogenesis, and therapeutic advances, we aim to resolve the GC therapeutic paradox and provide robust frameworks for future clinical management.